INKT - Mink Therapeutics Inc
Mink Therapeutics Inc Logo

INKT - Mink Therapeutics Inc

https://minktherapeutics.com
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.

52W High
$76.00
52W Low
$4.56
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.33
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.67
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
10.05
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
65.69%
Institutions (25–75% balanced)
1.37%
Shares Outstanding
4,522,900
Float
1,544,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-2.80
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-12.39%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—